Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial.
- S. Galimberti
- S. Luminari
- E. Ciabatti
- S. Grassi
- F. Guerrini
- A. Dondi
- L. Marcheselli
- M. Ladetto
- P. P. Piccaluga
- A. Gazzola
- C. Mannu
- L. Monitillo
- B. Mantoan
- I. D. Giudice
- I. D. Starza
- M. Cavalli
- L. Arcaini
- A. Tucci
- G. A. Palumbo
- L. Rigacci
- A. Pulsoni
- U. Vitolo
- C. Boccomini
- D. Vallisa
- G. Bertoldero
- P. Musto
- M. Petrini
- M. Federico
- GAIDANO, Gianluca
DOIAbstract
The role of the minimal residual disease (MRD) in follicular lymphoma is still debated. In this study, we assessed whether the BCL2/IGH rearrangement could have a prognostic role in patients receiving R-CHOP, R-FM, or R-CVP.DNAs from 415 patients among the 504 cases enrolled in the FOLL05 trial (NCT00774826) were centralized and assessed for the BCL2/IGH at diagnosis, at the end of treatment, and after 12 and 24 months.At diagnosis, the molecular marker was detected in 53\% of cases. Patients without molecular marker or with a low molecular tumor burden (<1 × 10(-4) copies) showed higher complete remission (CR) rate and longer progression-free survival (PFS; 3-year PFS 80\% vs. 59\%; P = 0.015). PFS was significantly conditioned by the PCR ...
Add to ORKG